SCYX 7158

Drug Profile

SCYX 7158

Alternative Names: AN-5568; Oxaborole SCYX-7158; SCYX-7158

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator Anacor Pharmaceuticals; SCYNEXIS
  • Developer Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation
  • Class Antiprotozoals; Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Trypanosomiasis

Most Recent Events

  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 08 Sep 2015 Drugs for Neglected Diseases Initiative Foundation and partners plans a pivotal phase IIb/III trial for Trypanosomiasis in Congo
  • 08 Sep 2015 Anacor Pharmaceuticals and the Drugs for Neglected Diseases Initiative Foundation completes a phase I trial in Trypanosomiasis (In volunteers) in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top